Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis
| Autor: | Gordana Bothe, Minoo Lenarz, Pee Win Chong, Katharina Stoelzel |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Pulmonary and Respiratory Medicine
Adult Glycerol Male medicine.medical_specialty Nasal Provocation Tests medicine.medical_treatment placebo-controlled Mucous membrane of nose Placebo medicine.disease_cause Nasal provocation test Phosphates Young Adult Allergen Double-Blind Method Immunology and Allergy Medicine Humans Plant Oils Antigens Dermatophagoides Saline Genetics (clinical) Administration Intranasal House dust mite allergic rhinitis biology business.industry allergy prevention Polysaccharides Bacterial Rhinitis Allergic Seasonal clinical trial Original Articles Nasal Sprays Middle Aged biology.organism_classification Dermatology Rhinitis Allergic respiratory tract diseases Clinical trial Treatment Outcome Nasal spray Immunology Bentonite Female business randomised Gels |
| Zdroj: | The Clinical Respiratory Journal |
| ISSN: | 1752-699X |
| Popis: | Background Nasya/Prevalin is a natural, drug-free nasal spray for treatment and prevention of allergic rhinitis. Because of its thixotropic property, it forms a barrier on the nasal mucosa, preventing allergen contact. This study assesses the clinical efficacy and safety of Nasya/Prevalin in a nasal provocation test with house dust mite allergens. Methodology/Principal In this randomised, double-blind, placebo-controlled trial, 20 subjects suffering from allergic rhinitis because of house dust mite allergens received a single dose of Nasya/Prevalin or saline spray before allergen challenge. Total nasal symptom score and total ocular symptom score were assessed 15, 30, 60, 75, 90, 120 and 240 min after challenge. Further, the appearance of the mucosa was examined by rhinoscopy. Results A single treatment with Nasya/Prevalin led to a significant reduction of TNSS at 60, 75 and 90 min after dust mite allergen challenge as compared with placebo (pVCAS = 0.021, pVCAS = 0.035, pVCAS = 0.036, respectively). Mucosa changes assessed by the rhinoscopic score (on swelling, secretion and colour) were significantly worse in the placebo group compared with the Nasya/Prevalin group (P = 0.033). Nasya/Prevalin was well tolerated, and the safety was comparable with placebo. Conclusions Treatment with Nasya/Prevalin was effective in preventing allergic reactions induced by dust mite allergen challenge. Please cite this paper as: Stoelzel K, Bothe G, Chong PW and Lenarz M. Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis. Clin Respir J 2014; 8: 382–390. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|